



COMPANY

Agilvax is a biotechnology company focused on the development of novel cancer therapeutics and vaccines against infectious diseases. The Company's lead asset is a novel human papillomavirus (HPV) vaccine, AX03, which provides protection against all cancer causing HPV types. AX03 is the ideal vaccine for the growing need and demand in emerging countries due to cost effective production and no need for refrigerated storage. In addition, Agilvax has multiple cancer therapeutics in development to treat breast cancer, lung cancer, and melanoma. Agilvax has secured \$3M in financing and executed several partnerships around its proprietary technology.

HIGHLIGHTS

First in Class Technology

- Unique Virus-Like-Particle (VLP) based technology for prevention and treatment of diseases with clinical unmet needs
- Innovative vaccine generating platform with rapid development time
- Cost effective, scalable, stable vaccines

Products

- Five Fully-Owned Products
- Solid Patent Protection of Products and Platforms
- Innovative and balanced portfolio (cancer and infectious disease)

External Validation

- National Institute of Health heavily investing in Agilvax HPV and Malaria Vaccine development
- Partnerships with leader Companies in ID space (IBT for Ebola and Humabs for RSV, Rabies and Norovirus infections)
- Last financing round (June 2015): \$3M total raised

OUR PIPELINE

Therapeutic Area	Indication	Development Process	Clinical Trials
Infectious Disease	HPV Human Papilloma virus	<div><div></div></div>	
Infectious Disease	RSV Respiratory Syncytial Virus	<div><div></div></div>	
Oncology	Breast Cancer Her2Neu-Vax	<div><div></div></div>	
Oncology	Lung Cancer xCT/CRR5-Vax	<div><div></div></div>	

TEAM

Federica Pericle, PhD, MBA
President and CEO

Michael Perrine, MS, MBA
Director of Business Development

Mitchell Tyler, PhD
Director of Research & Development

John O' Rourke, PhD
Director of Platform Technology

Gabriela Aguilar
Investor Relations

Constance Dorian
Director of Technical Operations


BOARD

Waneta Tuttle, PhD, MBA
CEO of Southwest Medical Ventures

Brian Birk
Managing Partner of Sun Mountain Capital


Ebetuel (Beto) Pallares, PhD
Joseph Advisory Services/
Hunt Holdings

Stuart Rose, PhD Founder
of The Bioscience Center and
FatPipe ABQ



UNIQUE VACCINE PLATFORM


Agilvax's technology is based on virus-like-particles (VLPs), which are structures that resemble viruses but lack viral genetic material making them non-infectious to humans. Agilvax has engineered vaccines that stimulate the production of antibodies to prevent infection or treat cancers. What sets Agilvax apart is the ability to rapidly discover and develop vaccines and therapeutics. The company is able to advance candidates through the preclinical proof of concept process at industry leading speed (six months). The products are also produced in a cost-effective manner and do not require refrigerated storage.



1. Cloned genes:
library or specific
antigens + VLP



2. Bacterial based
manufacturing



3. VLP vaccine
candidate

CREATING VALUE AT AGILVAX

Agilvax's lead infectious disease asset is a broadly protective next generation HPV vaccine, AX03, which is being developed in collaboration with the National Institutes of Health (NIH) and is in the manufacturing stage.

Agilvax's lead cancer therapeutic candidates target HER2/neu (human epidermal growth factor receptor 2) overexpressed in approximately 20% of breast cancer patients and associated with metastasis and poor prognosis. Her2neu vax represents a significant validation of the platform in the discovery and development of cancer therapeutics.

In collaboration with key partners, Agilvax is poised to identify and select lead vaccine and cancer therapeutic candidates. The Agilvax platform offers partners attractive licensing opportunities in a resource efficient manner to quickly test concepts and develop programs with a high probability of success.

ADVISORY BOARD

David Peabody, PhD

Professor, University of New Mexico

Bryce Chackerian, PhD

Associate Professor,
University of New Mexico

Doug Watts, MS, PhD

Professor, University of
Texas El Paso

Frank Borriello, MD, PhD

Baxter, Shire, Takeda,
Millenium

Enrico Braglia

OneLife, Helsinn

Agilvax, Inc.

5901 Indian School Rd NE
Albuquerque, NM 87110

(505) 200-9541

info@agilvax.com

www.agilvax.com